陳國寧+林澤輝+杜永明

[摘要] 目的 探討丹參川芎嗪注射液對缺血性腦卒中患者血清中同型半胱氨酸、高敏C反應(yīng)蛋白和血脂水平的影響以及臨床療效觀察。 方法 選取2014年2月～2016年11月在廣州中醫(yī)藥大學(xué)附屬海南省中醫(yī)院急診科治療的100例缺血性腦卒中患者，根據(jù)治療方案分為觀察組和對照組，每組各50例。對照組給予常規(guī)治療，觀察組加用丹參川芎嗪注射液。比較兩組患者血清中同型半胱氨酸、高敏C反應(yīng)蛋白和血脂水平，并評估兩組患者的臨床療效和NIHSS評分。 結(jié)果 治療后觀察組患者血清中同型半胱氨酸、高敏C反應(yīng)蛋白、總膽固醇、三酰甘油和脂蛋白a水平均明顯低于對照組，差異有統(tǒng)計學(xué)意義（P < 0.05）。觀察組臨床療效和NIHSS評分均優(yōu)于對照組，差異有統(tǒng)計學(xué)意義（P < 0.05）。 結(jié)論 丹參川芎嗪注射液能降低缺血性腦卒中患者血清同型半胱氨酸、高敏C反應(yīng)蛋白和血脂水平，提高臨床療效，優(yōu)化患者神經(jīng)功能改善。

[關(guān)鍵詞] 缺血性腦卒中；丹參川芎嗪注射液；同型半胱氨酸；高敏C反應(yīng)蛋白；血脂；臨床療效

[中圖分類號] R734 [文獻(xiàn)標(biāo)識碼] A [文章編號] 1673-7210（2018）01（a）-0076-04

[Abstract] Objective To explore the effect of Salvia Tetramethylpyrazine Injection on serum homocysteine， high-sensitivity C-reactive protein and lipid levels in ischemic stroke and clinical efficacy. Methods From February 2014 to November 2016， 100 patients with ischemic stroke in the emergency department of Chinese Medicine Hospital of Hainan Province， Guangzhou University of Chinese Medicine were selected and divided into treatment group and control group according to therapeutic schedule， with 50 cases in each group. The control group was treated with conventional treatment， while the treatment group was treated Salvia Tetramethylpyrazine Injection on the basis of control group. The serum homocysteine， high-sensitivity C-reactive protein， lipid levels， clinical efficacy， NIHSS score of the two groups were observed. Results After treatment， the levels of serum homocysteine， high-sensitivity C-reactive protein ， total cholesterol， triacylglycerol and lipoprotein （a） in the treatment group were lower than those in the control group， with statistically significant difference （ P < 0.05）. The NIHSS score and clinical efficacy of treatment group were significantly better than those of control group， with statistically significant difference （P < 0.05）. Conclusion Salvia Tetramethylpyrazine Injection can reduce the serum homocysteine， high sensitivity c-reactive protein and serum lipid levels in patients with ischemic stroke， improve the clinical efficacy and neurological function.

[Key words] Ischemic stroke； Salvia Tetramethylpyrazine Injection； Homocysteine； High-sensitivity C-reactive protein； Lipid； Clinical efficacy

缺血性腦卒中指腦血管狹窄或閉塞，導(dǎo)致其功能障礙而使腦組織發(fā)生缺血缺氧、軟化甚至壞死，從而引起一系列相關(guān)癥狀的疾病，具有極高的病死率和致殘率[1]。目前對于缺血性腦卒中的治療以改善腦循環(huán)，改善患者臨床癥狀，提高其生活質(zhì)量為主[2]。同時，由于這類患者再發(fā)病率高，如何降低患者再次發(fā)作的危險性，特別是針對病因的治療，顯得尤為關(guān)鍵。動脈粥樣硬化是該病最常見病變基礎(chǔ)。而動脈粥樣硬化與血清中同型半胱氨酸（homocysteine，Hcy）、高敏C反應(yīng)蛋白（high-sensitivity C-reactive Protein，hs-CRP）的高水平以及血脂代謝紊亂等呈相關(guān)性[3]。丹參川芎嗪注射液的主要成分為丹參素和川芎嗪，具有改善微循環(huán)及保護(hù)血管內(nèi)皮功能等重要作用[4]。為了探討其對缺血性腦卒中患者血清中Hcy、hs-CRP和血脂水平以及治療效果的影響，本研究對部分患者在常規(guī)治療基礎(chǔ)上加用丹參川芎嗪注射液，現(xiàn)將結(jié)果報道如下：endprint